ProKidney LP is a late clinical-stage cellular therapeutics company focused on CKD. The company's lead product candidate includes REACT(TM) is a first-of-its-kind, patented disease-modifying autologous cellular therapy. ProKidney LP, formerly known as Suvretta Holdings Corp. III, is based in WINSTON-SALEM, N,C.
| Revenue (Most Recent Fiscal Year) | $0.08M |
| Net Income (Most Recent Fiscal Year) | $-61.19M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -54267.64% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -15.03% |
| Current Ratio (Most Recent Fiscal Quarter) | 10.96 |
| Quick Ratio (Most Recent Fiscal Quarter) | 10.96 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-3.41 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.13 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.62 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.60 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 292.70M |
| Free Float | 171.26M |
| Market Capitalization | $210.89M |
| Average Volume (Last 20 Days) | 0.58M |
| Beta (Past 60 Months) | 1.50 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 41.49% |
| Percentage Held By Institutions (Latest 13F Reports) | 51.59% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |